Assessing clinical relevance of off-target effects observed at suprapharmacological concentrations of SGLT2 inhibitors. Reply.

Abdualrahman Mohammed Abdualkader, Rami Al Batran · 2026

Read Assessing clinical relevance of off-target effects observed at suprapharmacological concentrations of SGLT2 inhibitors. Reply. by Abdualrahman Mohammed Abdualkader, Rami Al Batran (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13626818.txt.

Description

Abdualrahman Mohammed Abdualkader and Rami Al Batran reply to a critic of their work on diabetes drugs called SGLT2 inhibitors. Their central claim is that these drugs directly switch on HMGCS2, a liver enzyme that helps make ketone fuel, backed by animal, genetic, cell, and test-tube evidence. Dr Taylor objected that the drug strengths used in human liver cells and in one binding assay far exceed what patients' blood ever carries.

The authors answer that those high strengths served target hunting, not dose claims. Free blood levels may also understate liver exposure. Carrier proteins pull the drug into the liver, and animal data show it pooling there. Mice fed the drug showed dose-linked enzyme activation at exposures matching human data. The exchange, printed as a formal reply, turns on how far lab doses can speak for the clinic.

Catalog record

CREATORAbdualrahman Mohammed Abdualkader, Rami Al Batran
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE5 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13626818

Browse the full library · About the Tower of Babel